RAS mutations, harboring more DNA hypermethylations, show the preferential association with AKT phosphorylation and are more likely to activate the PI3K/AKT pathway, which can occur in 30%-50% of FTC, 15% of PTC, 30%-45% of follicular variant papillary thyroid cancer (FVPTC), and 20%-40% of PDTC and ATC (13). This evidence concerns the gene AKT1 and thyroid cancer, nonmedullary, 2.